Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

Makoto Nishio; Fabrice Barlési; Howard West; S. Ball; Rodolfo Bordoni; Manuel Cobo; Pascale Dubray Longeras; Jerome H. Goldschmidt; Silvia Novello; Francesco Orlandi; Rachel E. Sanborn; Zsuzsanna Szalai; G. Ursol; Diana Mendus; Lijia Wang; Xiaohui Wen; Mark L. McCleland; Tien Hoang; See Phan; Mark A. Socinski

doi:10.1016/j.jtho.2020.11.025

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

IMpower132 met its co-primary PFS end point but not its co-primary OS end point, with numerical improvement for OS in the APP arm. APP had a manageable safety profile, with no new or unexpected safety signals identified.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nishio et al. (2020) studied this question.

synapsesocial.com/papers/69d99f61a1d151c65f6849c5 https://doi.org/10.1016/j.jtho.2020.11.025

View Full Paper

Ask AI

Bookmark

Share

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

Ask about this paper

Abstract

Discussion

Cite This Study

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading